In recent years, there has been mounting evidence that multiple metastases in the brain can be successfully treated with stereotactic radiosurgery (SRS). Evidence has also accrued to show that a single lung, spine, or other extracranial met can often be successfully treated—with durable results—using stereotactic ablative radiotherapy (SABR). But what about multiple metastases outside the brain? Until recently, these patients were typically offered palliative treatments, such as chemotherapy.

The ongoing SABR-COMET randomized trial, which looks at SABR for the comprehensive treatment of oligometastatic cancer, appears to suggest a change in paradigm of managing these patients. At ASTRO this year, David A. Palma, MD, PhD, presented long-term results of the study. He reported that the magnitude of benefit of SABR was greater than previously reported, and durable beyond five years.1

In this webinar, Dr. Palma talks with moderator Robert Timmerman, MD, about the SABR-COMET trial, the latest results, and the implications for the treatment of patients with multiple sites of metastasis.

 

Join us on Tuesday, December 8, 8:00 AM PT/11 AM ET:

Register

 

Speaker:

David Palma, M.D.

David Palma, M.D.
David Palma, MD, is a Professor at Western University and a Clinician-Scientist with the Ontario Institute for Cancer Research. His research focuses on translational imaging science, including evaluating new imaging and radiotherapy technologies in the pre-clinical and clinical settings. He is the chair of the Canadian Pulmonary Radiotherapy Investigators Group, which is focused on running pan-Canadian imaging-related randomized lung radiotherapy trials. Dr. Palma’s clinical practice focuses on the treatment of lung cancer, head and neck cancer, and oligometastatic disease.

Moderator:

Robert D. Timmerman, M.D.

Robert D. Timmerman, M.D.
Robert D. Timmerman, M.D., is Professor of Radiation Oncology and Neurosurgery, and Effie Marie Cain Distinguished Chair in Cancer Therapy Research at the University of Texas Southwestern Medical Center in Dallas, Texas, where his primary practice involves the treatment of adult and children with brain tumors. Dr. Timmerman has been the principal investigator or co-investigator on several prospective trials designed to evaluate the efficacy and toxicity of stereotactic body radiation therapy in lung, liver, spine, and pelvic sites. He is the national principal investigator of Radiation Therapy Oncology Group (RTOG) trials using this therapy in patients with early-stage lung cancer.

 

 

1Palma DA, Olson RA, Harrow S et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, Vol. 108, Issue 3, Supplement.

 

VarianVision Logo

Programs for sharing emerging ideas among thought leaders from across the globe, designed to spark inspiration, accelerate innovation, and advance patient care.